Abstract 18106: Estimation of Incident Heart Failure Risk in US Hispanics/Latinos Using a Validated Echocardiographic Risk Stratification Index: Echo Study of Latinos
Introduction: Based on the prevalence of cardiovascular risk factors, Hispanics/Latinos are considered at risk for symptomatic heart failure (HF). Nonetheless, there is a gap of information regarding the future impact of this population in the anticipated HF epidemic in the US.
Methods: Cross-sectional data derived from the Echo-Study of Latinos (ECHO-SOL) on participants older than 45 years of age without a history of symptomatic HF. The validated Echocardiographic Risk Stratification Index (ERSI) derived from echocardiographic parameters (LVMI, LAVI, mitral regurgitation grade, LVOT-VTI, presence of diastolic dysfunction) was applied to estimate incident HF risk. The index range was 0 to 8, with lower scores representing lower risk. The cohort was divided in two subpopulations: Low Risk (ERSI <3) and High Risk (ERSI ≥3). Survey statistics and weighted frequencies were used.
Results: 1,769 participants [57% women, mean age 56.3 (±0.37)] were included. The High Risk subpopulation represented 50.4% of the cohort and had significantly higher prevalence of obesity, hypertension and diabetes. The proportion of individuals in the High Risk subpopulation increased proportionally with older age; this held true for females and males (P 0.027 and 0.034, respectively). However, more females tended to be in the High Risk subpopulation at a younger age as compared to males (Figure). Individuals of Puerto Rican heritage had the highest proportion of High Risk participants (58.4%), whereas those of Mexican heritage had the lowest proportion (47.9%); however, this difference was not statistically significant (Figure).
Conclusions: This is the largest study of Hispanics/Latinos in the US describing a high prevalence of abnormal LV structure and function and its estimated risk for incident HF. Since Hispanics/Latinos represent a large and growing subset of the US population, the estimation of HF risk is a critical step for the implementation of cardioprotective strategies.
Author Disclosures: M.O. Rangel: None. R.C. Kaplan: None. M.L. Daviglus: None. D.W. Kitzman: None. M. Kansal: None. D.M. Spevack: None. A. Raisinghani: None. S.J. Shah: Research Grant; Significant; National Institutes of Health (R01 HL107577, R01 HL127028), the American Heart Association (16SFRN28780016, 15CVGPSD27260148). Other Research Support; Modest; Actelion, Novartis. Consultant/Advisory Board; Modest; AstraZeneca, Bayer, Merck, Novartis. C.J. Rodriguez: None.
- © 2016 by American Heart Association, Inc.